Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.3 (
collagenase
)
18,340
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Xeroderma pigmentosum group C
(
XPC
) interacts with hHR23B to recognize DNA damage in global genomic repair. We previously showed that
XPC
is predominantly affected by its hypermethylation and is associated with an increased occurrence of p53 mutation in lung cancer. Tumors with low
XPC
mRNA levels had a poorer prognosis than those with high
XPC
mRNA levels, suggesting that
XPC
defects may enhance tumor metastasis. However, the underlying mechanism is unclear. Here, we show that p53 transcriptional activity is modulated by
XPC
, whereby
XPC
stabilizes hHR23B to form an hHR23B-p53 complex that prevents p53 degradation. In addition, in lung cancer cells and xenograft tumors in nude mice, overexpression of
XPC
suppresses cell/tumor metastatic ability via repression of
matrix metalloproteinase-1
(
MMP1
) transcription by p53. Among tumors from lung cancer patients, those with low
XPC
mRNA also tended to have low expression of
MMP1
mRNA compared with those with high
XPC
mRNA. Patients with low
XPC
mRNA levels also more commonly had tumors with late-stage, distant metastasis (M1), nodal metastasis, and T value (P < 0.001 for tumor stage, distant metastasis, and nodal metastasis; P = 0.006 for t value). In conclusion, p53 dysfunction caused by
XPC
defects in lung cancers may enhance tumor metastasis via increased
MMP1
expression.
...
PMID:p53 dysfunction by xeroderma pigmentosum group C defects enhance lung adenocarcinoma metastasis via increased MMP1 expression. 2105 89